Soleno Therapeutics (NASDAQ:SLNO) Sees Strong Trading Volume – Here’s What Happened

Soleno Therapeutics, Inc. (NASDAQ:SLNO) saw unusually-high trading volume on Tuesday . Approximately 4,501,987 shares changed hands during mid-day trading, an increase of 78% from the previous session’s volume of 2,535,892 shares.The stock last traded at $52.2650 and had previously closed at $52.25.

Key Stories Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Neurocrine Biosciences agreed to acquire Soleno for $53.00 per share in cash (~$2.9B), giving SLNO a clear acquisition premium and likely the main reason the stock moved higher as buyout news surfaced. PR Newswire — Neurocrine to Acquire Soleno
• Neutral Sentiment: Trading in SLNO was temporarily halted ahead of the deal announcement (routine for material corporate news), which amplified overnight volatility when trading resumed. PR Newswire — Neurocrine to Acquire Soleno
• Neutral Sentiment: Some research shops (Wolfe) reaffirmed “peer perform” ratings even as the deal emerged — showing analysts are re‑pricing SLNO around the transaction level rather than endorsing organic upside. Benzinga — Wolfe Research
• Negative Sentiment: Numerous securities‑class action notices and law‑firm investigations were filed or announced (multiple firms reminding investors of a May 5 lead‑plaintiff deadline), increasing potential legal liabilities and post‑deal overhang. Newsfile — Faruqi & Faruqi class action notice
• Negative Sentiment: Soleno voluntarily withdrew its EU marketing application for its Prader‑Willi drug (VYKAT XR / DCCR), a regulatory setback that could factor into deal terms and future commercial potential outside the U.S. TipRanks — EU application withdrawal
• Negative Sentiment: Several analysts cut ratings/targets (Cantor Fitzgerald, TD Cowen, Lifesci) or reduced price targets sharply toward the $53 deal price, signaling limited upside beyond the announced takeover and reflecting uncertainty. Benzinga / Zacks — analyst moves

Wall Street Analysts Forecast Growth

SLNO has been the subject of several research reports. TD Cowen reiterated a “hold” rating and issued a $53.00 target price (down from $85.00) on shares of Soleno Therapeutics in a research report on Tuesday. Wells Fargo & Company cut their target price on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Cantor Fitzgerald lowered shares of Soleno Therapeutics from an “overweight” rating to a “hold” rating and cut their target price for the stock from $123.00 to $53.00 in a research report on Monday. Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a research report on Tuesday, January 13th. Finally, Lifesci Capital lowered shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $93.90.

Soleno Therapeutics Price Performance

The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $2.70 billion, a PE ratio of 227.21 and a beta of -2.81. The firm’s 50-day moving average is $37.99 and its 200-day moving average is $47.81.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.16. The business had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million. Equities analysts predict that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

Institutional Trading of Soleno Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Soleno Therapeutics by 1.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock worth $1,242,000 after purchasing an additional 189 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Soleno Therapeutics in the second quarter worth $25,000. Avanza Fonder AB lifted its stake in Soleno Therapeutics by 11.2% in the fourth quarter. Avanza Fonder AB now owns 3,195 shares of the company’s stock worth $148,000 after purchasing an additional 323 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Soleno Therapeutics by 11.9% during the third quarter. Principal Financial Group Inc. now owns 3,197 shares of the company’s stock valued at $216,000 after acquiring an additional 340 shares during the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of Soleno Therapeutics by 2.4% during the third quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock valued at $1,055,000 after acquiring an additional 360 shares during the last quarter. 97.42% of the stock is owned by institutional investors.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.